Novel molecular typing reveals the risk of recurrence in patients with early-stage papillary thyroid cancer.

These findings could help accurately and reliably identify PTC patients with high risk of recurrence so that they could receive more radical and aggressive treatment strategies and more rigorous surveillance practices.